Pneumatosis intestinalis during chemotherapy with nilotinib in a patient with chronic myeloid leukemia who tested positive for anti-topoisomerase I antibodies. | Canada Hyperbarics Skip to main content
Clinical Study Clinical journal of gastroenterology 2016

Pneumatosis intestinalis during chemotherapy with nilotinib in a patient with chronic myeloid leukemia who tested positive for anti-topoisomerase I antibodies.

Fujimi A, Sakamoto H, Kanisawa Y, Minami S, Nagamachi Y, Yamauchi N, et al. — Clinical journal of gastroenterology, 2016

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers described the case of a 55-year-old man with chronic myeloid leukaemia who developed pneumatosis intestinalis during nilotinib chemotherapy.

What They Found

A 55-year-old man with chronic myeloid leukaemia developed pneumatosis intestinalis approximately 5 months after starting nilotinib. This condition resolved with five courses of hyperbaric oxygen therapy and other medications, while nilotinib was continued, leading to major and complete molecular responses for his leukaemia at 6 and 18 months, respectively.

Canadian Relevance

This study has no direct Canadian connection.

Study Limitations

As a single case report, the findings of this study cannot be generalized to a broader patient population.

This plain-language summary is generated with AI assistance and checked against the source abstract before publication. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Clinical Study
Category Cardiac
Source Pubmed
PubMed ID 27638345
Year Published 2016
Journal Clinical journal of gastroenterology
MeSH Terms Antineoplastic Agents; Autoantibodies; DNA Topoisomerases, Type I; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pneumatosis Cystoides Intestinalis; Pyrimidines; Tomography, X-Ray Computed

Cite This Study

Share

Find a Canadian Clinic

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last reviewed: April 2, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology